Review Article
Volume 8 Issue 1 - 2021
Friend or Foe? Helicobacter pylori Infection: Epidemiology, Signs, and Symptoms, and Treatment
Nicholas A Kerna1,2*, Kyle Kadivi3, Olufemi Odugbemi4, John V Flores5,6, Hilary M Holets5.6, Shain Waugh7, Ijeoma Nnake2 and Fernand Jean-Baptiste8
11SMC–Medical Research, Thailand
22First InterHealth Group, Thailand
3Global Health Group LLC, USA
4Olabisi Onabanjo University, Nigeria
5Beverly Hills Wellness Surgical Institute, USA
6Orange Partners Surgicenter, USA
7Fettle Path, USA
8Department of Biological Sciences, Florida Atlantic University, USA
*Corresponding Author:Nicholas A Kerna, (mailing address) POB47 Phatphong, Suriwongse Road, Bangkok, Thailand 10500.
Received: November 30, 2020; Published: December 31, 2020




Abstract

pylori can induce gastritis, peptic ulcer diseases, and cancer, including mucosa-associated lymphoid tissue lymphoma. It is also associated with numerous comorbidities. Nevertheless, several purported positive impacts of the bacterium have been noted, such as maintaining the stomach's healthy environment. Non-pathogenic H. pylori strains may aid in normalizing excess stomach acids and regulating appetite. Patients with H. pylori infection can experience acute gastritis symptoms with acute-onset abdominal pain, nausea, and vomiting. Non-specific abdominal pain, a sense of bloating, belching, and appetite loss are signs of infection. However, about 90% of individuals infected with H. pylori may never experience any symptoms during their lifetime, although 10–20% are at risk for peptic ulcer disease. The precise routes of H. pylori transmission remain unclear, although contaminated food, water, or soil are strongly suspected as well as person-to-person transmission through feco-oral and oral-oral routes. Treatment with antibacterial and antisecretory agents is the standard of care for H. pylori management. Also, phytomedicines and probiotics have been reported effective not only as a treatment but also in lessening the side effects of antimicrobial therapy, such as diarrhea. There are various drug combinations for eradicating H. pylori, as described in this paper. Although the recurrence rate of H. pylori infection after eradication is relatively low, it remains a cause for concern and antibiotic resistance. Poor socio-economic conditions and sanitary habits are risk factors associated with the recurrence of H. pylori infection after successful eradication.

Keywords: Dyspepsia; Heartburn; Hematemesis; Melena; Peptic Ulcer; Phytomedicines; Probiotic; Triple-Drug Therapy

References

  1. Alfarouk KO., et al. “The possible role of helicobacter pylori in gastric cancer and its management”. Frontiers in Oncology 9 (2019): 75.
  2. Brown LM. “Helicobacter pylori: Epidemiology and routes of transmission”. Epidemiologic Reviews2 (2000): 238-297.
  3. Backert S., et al. “Pathogenesis of Helicobacter pylori infection”. Helicobacter1 (2016): 19-25.
  4. Camilo V., et al. “Pathogenesis of Helicobacter pylori infection”. Helicobacter 1 (2017).
  5. Kusters JG., et al. “Pathogenesis of Helicobacter pylori infection”. Clinical Microbiology Reviews3 (2006): 449-490.
  6. Sanders MK and Peura DA. “Helicobacter pylori-Associated Diseases”. Current Gastroenterology Reports 4.6 (2002): 448-454.
  7. Marshall B and Warren R. “Unidentified Curved Bacilli on Gastric Epithelium In Active Chronic Gastritis”. The Lancet 1 (1983): 1237-1275.
  8. Gravina AG., et al. “Helicobacter pylori and extragastric diseases: A review”. World Journal of Gastroenterology 29 (2018): 3204-3221.
  9. Laird-Fick HS., et al. “Gastric adenocarcinoma: The role of helicobacter pylori in pathogenesis and prevention efforts”. Postgraduate Medical Journal (2016).
  10. Bravo D., et al. “Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects”. World Journal of Gastroenterology28 (2018): 3071-3089.
  11. Blaser MJ. “Who are we? Indigenous microbes and the ecology of human diseases”. EMBO Reports10 (2006): 956-960.
  12. Blaser M. “Antibiotic overuse: Stop the killing of beneficial bacteria”. Nature7361 (2011): 393-394.
  13. Pounder RE NgD. “The prevalence of Helicobacter pylori infection in different countries”. In: Alimentary Pharmacology and Therapeutics2 (1995): 33-39.
  14. Burucoa C and Axon A. “Epidemiology of Helicobacter pylori infection”. Helicobacter1 (2017): 1-5.
  15. Malaty HM. “Epidemiology of Helicobacter pylori infection”. Best Practice and Research: Clinical Gastroenterology2 (2007): 205-214.
  16. Narayanan M., et al. “Peptic Ulcer Disease and Helicobacter pylori infection”. Malignant Hyperthermia 3 (2018): 219-224.
  17. Talley NJ., et al. “ABC of the upper gastrointestinal tract: Indigestion: When is it functional?” BMJ: British Medical Journal 7324 (2001): 1294-1297.
  18. Kim BS., et al. “Diagnosis of gastrointestinal bleeding: A practical guide for clinicians”. World Journal of Gastrointestinal Pathophysiology 4 (2014): 467-478.
  19. McColl KEL. “Helicobacter pylori infection”. New England Journal of Medicine (2010).
  20. Crowe SE. “Helicobacter pylori Infection”. New England Journal of Medicine (2019).
  21. Suerbaum S and Michetti P. “Helicobacter pylori infection”. New England Journal of Medicine 15 (2002): 1176-1186.
  22. Salih BA. “Helicobacter pylori infection in developing countries: the burden for how long?” Saudi Journal of Gastroenterology 3 (2009): 201-207.
  23. Peterson WL. “The role of antisecretory drugs in the treatment of Helicobacter pylori infection”. Alimentary Pharmacology and Therapeutics 1 (1997): 21-25.
  24. Malfertheiner P., et al. “Management of helicobacter pylori infection-the Maastricht V/Florence consensus report”. Gut (2017).
  25. Safavi M., et al. “Treatment of Helicobacter pylori infection: Current and future insights”. The World Journal of Clinical Cases 1 (2016): 5-19.
  26. Yang JC., et al. “Treatment of Helicobacter pylori infection: Current status and future concepts”. World Journal of Gastroenterology18 (2014): 5283-5293.
  27. De Brito BB., et al. “Pathogenesis and clinical management of Helicobacter pylori gastric infection”. World Journal of Gastroenterology37 (2019): 5578-5589.
  28. Lambert JR and Midolo P. “The actions of bismuth in the treatment of Helicobacter pylori infection”. Alimentary Pharmacology and Therapeutics1 (1997): 27-33.
  29. Kawakami Y., et al. “In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori”. Antimicrobial Agents and Chemotherapy2 (2000): 458-461.
  30. Saleem N and Howden CW. “Update on the Management of Helicobacter pylori Infection”. Current Treatment Options in Gastroenterology (2020): 1-12.
  31. Chey WD and Wong BCY. “American College of Gastroenterology guideline on the management of Helicobacter pylori infection”. American Journal of Gastroenterology8 (2007): 1808-1825.
  32. Fock KM., et al. “Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection”. Journal of Gastroenterology and Hepatology10 (2009): 1587-1600.
  33. Graham DY and Fischbach L. “Helicobacter pylori treatment in the era of increasing antibiotic resistance”. Gut8 (2010): 1143-1153.
  34. Furuta T., et al. “Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori”. Clinical Pharmacology and Therapeutics 4 (2007): 521-528.
  35. Hu Y., et al. “Recent progress in Helicobacter pylori treatment”. Chinese Medical Journal 3 (2020): 335-343.
  36. Zullo A., et al. “High eradication rates of Helicobacter pylori with a new sequential treatment”. Alimentary Pharmacology and Therapeutics 5 (2003): 719-726.
  37. Chen YI and Fallone CA. “A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: A Canadian study conducted in a 'real world' setting”. Canadian Journal of Gastroenterology and Hepatology 8 (2015): e7-e10.
  38. Xue Y., et al. “Recurrence of Helicobacter pylori infection”. Chinese Medical Journal7 (2019): 765-771.
Citation: Kerna NA, Kadivi K, Odugbemi O, Flores JV, Holets HM, Waugh S, Nnake I, Jean-Baptiste F. “Friend or Foe? Helicobacter pylori Infection: Epidemiology, Signs, and Symptoms, and Treatment”. EC Gastroenterology and Digestive System 8.1 (2021): 59-65.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


December Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the December issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 17, 2021.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk